Drug intelligence / Profile preview

erlotinib + rilotumumab

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Erlotinib + rilotumumab is a combination therapy consisting of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and rilotumumab (AMG 102), a fully humanized monoclonal antibody (IgG2) that neutralizes hepatocyte growth factor (HGF), thus preventing MET activation. This combination targets both the EGFR pathway and the HGF/MET pathway, which is implicated in resistance to EGFR inhibitors. The combination has been studied primarily for the treatment of non-small cell lung cancer (NSCLC), particularly in previously treated patients.

Brand names: Tarceva
Other names: AMG 102 + erlotinibrilotumumab + erlotinib

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on erlotinib + rilotumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + rilotumumab.

Explore the full profile